• Strategic Proteasome Inhibition with MG-132: Mechanistic ...

  2025-10-03

  Explore how MG-132, a potent and cell-permeable proteasome inhibitor peptide aldehyde, empowers translational researchers by dissecting the ubiquitin-proteasome system (UPS), elucidating apoptosis and cell cycle arrest in cancer models, and advancing the frontier of ferroptosis and proteostasis research. This thought-leadership article provides mechanistic rationale, experimental guidance, and a strategic outlook, while integrating recent findings on ferroptosis resistance and highlighting how MG-132 uniquely positions your research at the intersection of cancer biology and next-generation therapeutic development.

• CB-5083: Selective p97 Inhibitor Empowering Cancer Research

  2025-10-02

  CB-5083 stands out as a highly selective, orally bioavailable p97 inhibitor that enables targeted disruption of protein homeostasis and apoptosis induction in cancer research. This guide delivers practical workflows, advanced use-cases, and actionable troubleshooting tips to maximize CB-5083’s impact in both in vitro and in vivo studies.

• CB-5083 and the Next Frontier of Protein Homeostasis Disr...

  2025-10-01

  This thought-leadership article delves into the advanced mechanistic rationale for targeting p97/valosin-containing protein with CB-5083, a highly selective and orally bioavailable p97 inhibitor. We synthesize recent scientific findings on ER quality control, protein degradation, and lipid regulation, offering translational researchers strategic guidance for leveraging CB-5083 in cancer research. By quoting and contextualizing recent discoveries, we position CB-5083 as more than a standard tool compound—charting a visionary path for future investigations in oncology and cell biology.

• CB-5083: A Selective p97 Inhibitor Transforming Tumor Res...

  2025-09-30

  CB-5083 stands out as an orally bioavailable, selective p97 AAA-ATPase inhibitor, enabling researchers to dissect protein and lipid homeostasis in cancer and metabolic models. Its precision in disrupting protein degradation pathways and inducing apoptosis yields robust, quantifiable tumor growth inhibition, setting a new benchmark for translational oncology and ER stress biology.

• MG-132 in Chromatin Dynamics: Proteasome Inhibition and E...

  2025-09-29

  Explore how MG-132, a potent proteasome inhibitor peptide aldehyde, uniquely links ubiquitin-proteasome system inhibition to chromatin phase transitions and cell fate. Delve into advanced applications in apoptosis research and epigenetic regulation not found in existing guides.

• Verapamil HCl: Targeting TXNIP for Innovative Bone and In...

  2025-09-28

  Explore how Verapamil HCl, a phenylalkylamine L-type calcium channel blocker, uniquely modulates TXNIP-driven pathways in bone and inflammatory disease models. This article reveals advanced mechanisms and translational potential, offering novel insights beyond conventional calcium channel inhibition.

• Verapamil HCl: Deciphering TXNIP-Linked Pathways in Bone ...

  2025-09-27

  Discover how Verapamil HCl, a leading L-type calcium channel blocker, uniquely modulates TXNIP-driven calcium signaling and apoptosis in myeloma and arthritis research. This article reveals advanced mechanistic insights and research applications that go beyond conventional approaches.

• CB-5083: Selective p97 Inhibition as a Precision Tool for...

  2025-09-26

  Explore how CB-5083, a potent p97 inhibitor, uniquely enables advanced interrogation of ER-associated protein and lipid homeostasis in cancer and metabolic research. This article reveals mechanistic insights and analytical strategies not found in standard reviews.

• L1023 Anti-Cancer Compound Library: Unlocking Precision O...

  2025-09-25

  Explore how the L1023 Anti-Cancer Compound Library empowers precision cancer research by enabling target-specific drug discovery and biomarker-driven screening. Discover advanced strategies that go beyond high-throughput screening to accelerate the identification of novel anti-cancer agents.

• Annexin V: Advanced Applications in Apoptosis and Immune ...

  2025-09-24

  Explore the cutting-edge role of Annexin V as an apoptosis detection reagent and phosphatidylserine binding protein in deciphering early apoptosis, immune tolerance, and disease mechanisms. This article offers novel insights into Annexin V's use in translational cell death research, setting it apart from standard assay guides.

• Annexin V as a Precision Probe in Immune Cell Apoptosis a...

  2025-09-23

  Explore the pivotal role of Annexin V as a phosphatidylserine binding protein in advanced apoptosis detection assays and its unique applications in immune tolerance research, including preeclampsia models. This article provides a rigorous perspective on leveraging Annexin V for mechanistic insights into cell death and immune regulation.

• br Methods br Results br Discussion br Acknowledgements

  2025-03-03

  

  Methods Results Discussion Acknowledgements This work was supported by the National Institutes of Health [Grant R21 NS081429], a Pilot Grant from the Vanderbilt Conte Center supported by the National Institutes of Health [Grant P50 M096972], and by the Department of Anesthesiology at V

• br Methods br Results From a study population

  2025-03-03

  

  Methods Results From a study population of 7069 patients, a total of 149 falls were reported during the study GMX1778 for an incidence rate (IR) of 5.2 falls per 1000 patient-days (PD), 95% confidence interval (CI) 4.4/1000 PD–6.1/1000 PD. The incidence rate ratio (IRR) for patients in the AC

• br Introduction In the past two

  2025-03-01

  

  Introduction In the past two decades, graphene and graphene based nanomaterials with unique physicochemical properties have attracted great attentions in many fields including biomedicine and biotechnology. Graphene oxide (GO) and its derivatives have shown promising potential as biological and c

• In this study we showed that

  2025-03-01

  

  In this study, we showed that TRIM48 promotes ASK1 activation through ubiquitination-dependent degradation of a negative regulator of ASK1 activation, protein arginine methyltransferase 1 (PRMT1). Knocking down TRIM48 suppressed oxidative-stress-induced cell death mediated by ASK1, and the additiona

15978 records 5/1066 page Previous Next 12345 下5页 Last page